FTC final order halts TruHeight kids’ height claims—what the order requires
July 15, 2026: The FTC’s final order against TruHeight (Vanilla Chip LLC) restricts “clinical tests prove” kids’ height claims unless the Order’s strict human-clinical evidence standard is met.
On July 15, 2026, the Federal Trade Commission issued a final Decision and Order against Vanilla Chip LLC, doing business as TruHeight, and two principals, Eden Stelmach and Justin Rapoport—permanently restraining the company from making certain children’s height and height-growth advertising claims unless it can meet the Order’s demanding substantiation standard.
The Order also limits how TruHeight can use customer reviews and testimonials in marketing, including rules aimed at misrepresenting who provided a review or whether a reviewer actually used the product, and rules against incentives tied to review “sentiment.”
What the FTC finalized on July 15, 2026
This is an FTC administrative Decision and Order that resolves the matter through a consent process. The company and principals stated they neither admit nor deny the complaint’s allegations (except for facts needed for jurisdiction), and the Commission accepted the consent agreement and issued the final Order.
What the FTC permanently bans (unless strict proof exists)
Under the Order’s main provisions, TruHeight and the covered individuals are permanently restrained and enjoined from making (or assisting others in making) representations that a Covered Product:
- causes increased height of children or teenagers,
- causes increased height growth in children or teenagers, or
- “clinical tests prove” either increased height or increased height growth in children or teenagers
Those representations can only be made if they are non-misleading and, at the time the claim is made, TruHeight possesses and relies on “competent and reliable scientific evidence” substantiating the representation.
How demanding the Order’s “scientific evidence” bar is
The Order defines “competent and reliable scientific evidence” to require, for covered height/height-growth claims, randomized, double-blind, placebo-controlled human clinical testing of the Covered Product (or of an “Essentially Equivalent Product”). The Order also requires that underlying/supporting data and relevant documents be available for FTC inspection and production, and it places the burden of proving “Essentially Equivalent Product” status on respondents.
What changes about reviews and testimonials
The Order also restricts specific testimonial and review practices:
- No misrepresenting reviewers/testimonialists. TruHeight is barred from claims that a reviewer/testimonialist exists, used the product, or had the experience stated in the review/testimonial when those statements would be inaccurate or misleading.
- No sentiment-conditioned review buying. TruHeight is barred from offering compensation or incentives in exchange for, or conditioned expressly or by implication on, creating consumer reviews that express a particular sentiment (positive or negative) about the product.
Money relief and payment deadlines (and what “effective date” means)
The Order includes monetary relief: a $4,000,000 liability, with a required $750,000 payment. Deadlines run from the Order’s effective date, which the Order specifies as the date it is published on the FTC website as a final order.
- $300,000 within 8 days of the effective date
- $225,000 within 4 months of the effective date
- $225,000 within 8 months of the effective date
After the $750,000 is fully paid, the Order states that the liability is suspended, subject to the Order’s conditions.
What parents and supplement shoppers should watch next
This isn’t a ban on all TruHeight advertising. It’s a targeted restraint on specific children’s height/height-growth claims—and on particular review/testimonial practices—unless the company can satisfy the Order’s strict scientific-evidence definition.
Practical takeaway for families: if you see kids’ height or height-growth claims, especially language suggesting “clinical tests prove” measurable results, treat those as high-risk marketing statements that require very specific human-clinical substantiation. Be extra cautious with testimonials or reviews that appear “managed,” especially where incentives are involved or where reviewer claims seem too scripted to be genuine.
Sources
Discover more from Interactive News
Subscribe to get the latest posts sent to your email.
